Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
B 21.78 4.01% 0.84
ACAD closed down 9.15 percent on Tuesday, January 18, 2022, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ACAD trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 3.49%
MACD Bearish Centerline Cross Bearish 3.49%
180 Bearish Setup Bearish Swing Setup 3.49%
Expansion Pivot Sell Setup Bearish Swing Setup 3.49%
Stochastic Reached Oversold Weakness 3.49%
Oversold Stochastic Weakness 3.49%
50 DMA Support Bullish -5.99%
Bullish Engulfing Bullish -5.99%
50 DMA Support Bullish -2.12%
Doji - Bullish? Reversal -2.12%
Older End-of-Day Signals for ACAD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Resistance 12 minutes ago
Up 5% 12 minutes ago
60 Minute Opening Range Breakout 25 minutes ago
Rose Above 50 DMA about 1 hour ago
Up 3% about 1 hour ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ACADIA Pharmaceuticals Inc. Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Industry Medication Chemical Compounds Alzheimer's Disease Parkinson's Disease Schizophrenia Chronic Pain Neurological Disorders Central Nervous System Disorders Nervous System Disorders Glaucoma Urological Disorders Treatment Of Parkinson's Disease Treatment Of Chronic Pain Treatment Of Glaucoma Treatment Of Schizophrenia Treatment Of Alzheimer's Disease Psychosis Muscarinic Agonist

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 54.5792
52 Week Low 15.6792
Average Volume 1,674,842
200-Day Moving Average 20.73
50-Day Moving Average 21.79
20-Day Moving Average 23.37
10-Day Moving Average 22.64
Average True Range 1.38
ADX 15.97
+DI 17.00
-DI 21.50
Chandelier Exit (Long, 3 ATRs) 23.04
Chandelier Exit (Short, 3 ATRs) 24.99
Upper Bollinger Bands 25.95
Lower Bollinger Band 20.79
Percent B (%b) 0.03
BandWidth 22.08
MACD Line -0.01
MACD Signal Line 0.37
MACD Histogram -0.373
Fundamentals Value
Market Cap 3.33 Billion
Num Shares 159 Million
EPS -1.97
Price-to-Earnings (P/E) Ratio -10.65
Price-to-Sales 19.85
Price-to-Book 12.93
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.85
Resistance 3 (R3) 24.16 23.49 23.37
Resistance 2 (R2) 23.49 22.75 23.34 23.20
Resistance 1 (R1) 22.22 22.29 21.89 21.91 23.04
Pivot Point 21.55 21.55 21.39 21.40 21.55
Support 1 (S1) 20.28 20.81 19.95 19.97 18.84
Support 2 (S2) 19.61 20.35 19.46 18.68
Support 3 (S3) 18.34 19.61 18.52
Support 4 (S4) 18.03